PACE-CME.org was present at ACC Scientific Sessions 2018 in Orlando, FL, USA. Find coverage of the latest CV news on PACE-CME.
ACC 2018 Steven Nissen compares ODYSSEY OUTCOMES with FOURIER and concludes that the results of these 2 studies in 2 different patient populations reinforce our understanding of the benefit of reducing LDL-c levels in patients with moderate LDL-c levels.
ACC 2018 Prof. Ray considers current insights on the class of PCSK9 inhibiting monoclonal antibodies, and he looks ahead at another PCSK9 inhibiting agent.
ACC 2018 Prof. Connolly summarizes the results of the interim analysis of the ANNEXA-4 trial: andexanet was effective in the reversal of the effect of FXa inhibitors and reversed FXa-associated bleedings in patients with acute major bleedings.
ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.
ACC 2018 In patients post-STEMI, treatment with ticagrelor resulted in similar rate of TIMI-bleedings as clopidogrel after 30 days in the TREAT trial.
ACC 2018 A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.
ACC 2018 Black barbershops and pharmacists worked together to improve high BP in non-hispanic black men. In a randomized design, a pharmacist intervention led to 27 mmHg drop in SBP over 6 months, vs. 9 mmHg in controls.
ACC 2018 In an interim analysis of the ANNEXA-4 study, andexanet rapidly reversed anti-FXa activity with an acceptable rate of adverse events in patients on FXa inhibitors with major bleeding.
ACC 2018 Due to the observed link between inflammation and aberrant insulin regulation, a key secondary outcomes of the CANTOS trial was new onset T2DM in patients with prediabetes at baseline.
ACC 2018 Mary Norine Walsh is the president of the ACC. She opened the congress by talking about the need for cardiologists to act as advocates, for quality, for each other, for patients, to create a better healthcare system.
ACC 2018 A new analysis of the CANTOS trial showed that IL-1β inhibition in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.
ACC 2018 The MANAGE trial studied the effect of dabigatran in patients with myocardial injury after non-cardiac surgery. After a mean of 16 months follow-up, a relative risk reduction of 28% in major vascular complications was seen.